David Creech, MD
Ophthalmology · Dover, DENPI 1659607406
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (36.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 39.4% of the total. Reporting peaked in 2019 at $8,692 and has fallen 57.6% since, to $3,689 in 2025. Among ophthalmology clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 154 payments — averaging $143.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$9K
- Sight Sciences, Inc.$7K
- Alcon$2K
- AbbVie$2K
- Ivantis, Inc$915
- Ocular Therapeutix, Inc.$191
- plus $855 from 17 others
What the payments were for
- Consulting fees$8,09237%
- Speaking & faculty fees$6,00027%
- Travel & lodging$1,9119%
- Food & beverage$6,04227%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 16 | $8,689 |
| Sight Sciences, Inc. | 14 | $6,979 |
| Alcon | 38 | $2,223 |
| AbbVie(2 entities) | 36 | $2,194 |
| Ivantis, Inc | 4 | $915 |
| Ocular Therapeutix, Inc. | 6 | $191 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $156 |
| Aerie Pharmaceuticals, Inc. | 5 | $94 |
| Tepha Inc | 1 | $87 |
| Dompe US, Inc. | 3 | $69 |
| W. L. Gore & Associates, Inc. | 1 | $59 |
| Eyepoint US, Inc. | 2 | $51 |
| Novartis | 3 | $48 |
| Rxsight Inc | 2 | $47 |
| Amgen | 3 | $45 |
| Sun Pharmaceutical Industries Inc. | 2 | $37 |
| Thea Pharma Inc. | 1 | $31 |
| Omeros Corporation | 2 | $29 |
| Kala Pharmaceuticals, Inc. | 1 | $24 |
| Bausch & Lomb Americas Inc. | 1 | $23 |
| Oasis Medical, Inc. | 2 | $20 |
| NEW World Medical,inc. | 1 | $20 |
| Rayner Intraocular Lenses Limited | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$6,839
- SION SURGICAL INSTRUMENT$3,239
- Whitestar Phacoemulsficiation System$2,520
- Tecnis Symfony IOL$2,132
- Premium Cataract IOLs$1,907
- DURYSTA$650
- Hydrus$639
- Hydrus Microstent$416
- Tecnis IOL$230
- Clareon$141
- ARGOS$141
- AcrySof$140
- VERITAS Vision System$140
- XEN$128
- Centurion$114
- Tecnis Simplicity$107
- CATALYS SYSTEM$107
- OMNI$104
How this compares
$22,045 in reported general payments places this provider in the 95th percentile of 49 ophthalmology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 68 | $37,401 |
| LumiganBimatoprost | 82 | $37,097 |
| IlevroNepafenac | 52 | $19,271 |
| Prednisolone Acetate | 442 | $17,741 |
| Difluprednate | 152 | $11,953 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $11,563 |
| Ketorolac Tromethamine | 408 | $9,402 |
| Loteprednol Etabonate | 22 | $6,057 |
| ProlensaBromfenac Sodium | 17 | $5,591 |
| Latanoprost | 257 | $4,895 |
| Alphagan PBrimonidine Tartrate | 18 | $4,099 |
| Travoprost | 22 | $3,566 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 220 | $3,217 |
| Brinzolamide | 17 | $2,865 |
| Brimonidine Tartrate | 69 | $2,782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $2,194 | $52,758124 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $94 | $37,40168 claims |
| NovartisIlevro | $48 | $19,27152 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa | $156 | $11,64839 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 ophthalmology providers in Delaware.
Other ophthalmology in Dover
- Bryan SeiffDover$9K
- David LuDover$5K
- Timothy DoyleDover$3K
- Jeffrey MinkovitzWilmington$7K
- Heather DealyWilmington$6K
- Stewart SmithWilmington$6K
- Richard SherryWilmington$5K
- Karen RudoMilford$5K
- Scott FudembergRehoboth Beach$5K
- Michael BrosmanWilmington$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.